에 대한 최신 뉴스 Arrowhead Pharma (NASDAQ:ARWR) 주식

Arrowhead Pharma

Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.

Mid Cap

News

Movers

Trading Ideas

ACHR

ARWR

BHVN

Hims & Hers Health, Inc. Class A Common Stock

HIMS

IREN

JOBY

SOUN

SRPT

SRRK

URBN

이 8개 중형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 아처 에비에이션(NYSE:ACHR) 주식은 지난주 65.57% 급등했다.

아처 및 어번 아웃피터스는 지난주 최고 성과를 보여준 8개 중형주 중 일부 (11월 25일-29일)

Large Cap

CPRT

ESTC

EXAS

MRNA

RIVN

RKLB

SNAP

ULTA

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 리비안 오토모티브(NASDAQ:RIVN)의 주식이 22.06% 급등했다. 이는 회사가 66억 달러의 에너지부(DOE)의 대출 약정을 확보한 후 발생한 일이다.

리비안, 로켓랩 및 모더나가 지난주 최고 성과를 보여준 10개 대형주 중 일부 (11월 25일-29일)

Biotech

Earnings

Equities

Markets

AMGN

RPRX

목요일 시장 마감 후 암젠(NASDAQ:AMGN)은 1분기 재무 결과를 발표했다. 여기에는 몇 가지 핵심 내용을 보자. 세부 사항 (The Details): 암젠은 분기별 이익을 주당 3.96달러로 보고했는데, 이는 분석가 컨센서스인 3.87달러보다 2.33% 높았다. 이 회사는 호라이즌(Horizon) 인수로 인한 운영 및 이자 비용 증가로 인해 주당순이익(EPS)이 1% 감소했으며 매출 증가로 부분적으로 상쇄되었다고 밝혔다.

암젠: 예상보다 좋은 1분기 실적 및 5,000만 달러의 마일스톤 지급금 수입에 주가 급등

Arrowhead Pharmaceuticals, Inc. - Common Stock

Arrowhead Pharmaceuticals Inc

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Arrowhead Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) with a Buy and maintains $80 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $80 Price Target

Chardan Capital analyst Keay Nakae maintains Arrowhead Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) with a Buy and maintains $60 price target.

Chardan Capital Maintains Buy on Arrowhead Pharma, Maintains $60 Price Target

Arrowhead Pharmaceuticals Announced Interim Results From A Phase 1/2A Clinical Study Of ARO-CFB, The Company's Investigational RNA Interference (RNAi) Therapeutic Targeting Complement Factor B Being Developed As A Potential Treatment For Complement Mediated Diseases

HC Wainwright &amp; Co. analyst Patrick Trucchio maintains Arrowhead Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) with a Buy and raises the price target from $60 to $80.

HC Wainwright & Co. Maintains Buy on Arrowhead Pharma, Raises Price Target to $80

<ul>
<li>In preclinical studies, investigational ARO-ALK7 silenced Activin receptor-like kinase 7 (ALK7) expression in adipose tissue, which led to reduced body weight and fat mass with preservation of lean muscle</li>
</ul>

Health Care

General

Arrowhead Pharmaceuticals Has Filed A Request For Regulatory Clearance To Initiate A Phase 1/2a Trial Of ARO-ALK7 As A Potential Treatment For Obesity

These eight mid-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>Archer Aviation Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) shares skyrocketed 65.57% last week.</li>
<li>Scholar Rock Holding Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRRK#NASDAQ">SRRK</a>) stock jumped 49.61%  after rival Biohaven Ltd.'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHVN#NYSE">BHVN</a>) taldefgrobep for spinal muscular <a href="https://www.benzinga.com//node/42169246" target="_blank" rel="noreferrer noopener">atrophy failed its Phase 3 study</a>.</li>
<li>Arrowhead Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) shares escalated 42.40% after it entered into a global licensing and collaboration agreement with Sarepta Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) for multiple clinical <a href="https://www.benzinga.com//node/42196870" target="_blank" rel="noreferrer noopener">and preclinical siRNA programs</a>.</li>
<li>Iris Energy Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>) stock surged 38.99% after the company reported first-quarter results and several analysts raised <a href="https://www.benzinga.com//node/42214256" target="_blank" rel="noreferrer noopener">the price forecast on the stock</a>.</li>
<li>Hims &amp; Hers Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) shares upped 33.42% in response to President-elect Donald Trump's plans to nominate Marty Makary to lead the <a href="https://www.benzinga.com//node/42177219" target="_blank" rel="noreferrer noopener">Food and Drug Administration (FDA)</a>.</li>
<li>SoundHound AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) stock grew 33.38%. The company recently announced the deployment of its conversational AI agent, Amelia, at <a href="https://www.benzinga.com//node/42145826" target="_blank" rel="noreferrer noopener">Apivia Courtage as part of the AEMA Group</a>.</li>
<li>Joby Aviation, Inc.'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>) stock upped 31.62% after Toyota Motor Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TM#NYSE">TM</a>) <a href="https://www.benzinga.com//node/42169194" target="_blank" rel="noreferrer noopener">invested half a billion dollars</a> in it.</li>
<li>Urban Outfitters, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>) shares increased 30.43% after the company reported third-quarter earnings and several analysts raised <a href="https://www.benzinga.com//node/42221225" target="_blank" rel="noreferrer noopener">the price forecast on the stock</a>.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/12/42256613/rivian-automotive-rocket-lab-and-moderna-are-among-top-10-large-cap-gainers-last-week-nov-25-nov-29-are-the-others-in-your-portfolio" target="_blank" rel="noreferrer noopener">Rivian Automotive, Rocket Lab And Moderna Are Among Top 10 Large-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio?</a></li>
<li><a href="https://www.benzinga.com/news/large-cap/24/12/42256757/reddit-grab-and-autodesk-are-among-top-11-large-cap-losers-last-week-nov-25-nov-29-are-the-others-in-your-portfolio" target="_blank" rel="noreferrer noopener">Reddit, Grab And Autodesk Are Among Top 11 Large-Cap Losers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio?</a></li>
</ul>
Image via Archer

Archer Aviation, Hims & Hers Health And Urban Outfitters Are Among Top 8 Mid-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio?

These ten large-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>Rivian Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) shares jumped 22.06% after securing a<a href="https://www.benzinga.com//node/42184005" target="_blank" rel="noreferrer noopener"> $6.6 billion DOE loan commitment</a>.</li>
<li>Rocket Lab USA, Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) stock surged 21.73% after it secured a $23.9 million CHIPS Act grant to enhance its <a href="https://www.benzinga.com//node/42216210" target="_blank" rel="noreferrer noopener">semiconductor operations in New Mexico</a>.</li>
<li>Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) stock upped 20.67% after the company announced a global licensing and collaboration agreement with Arrowhead Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) for <a href="https://www.benzinga.com//node/42196870" target="_blank" rel="noreferrer noopener">multiple clinical and preclinical siRNA programs</a>.</li>
<li>Exact Sciences Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) stock increased 16.98%. The Centers for Medicare &amp; Medicaid Services posted final payment determinations for its <a href="https://www.benzinga.com//node/42195803" target="_blank" rel="noreferrer noopener">2025 Clinical Laboratory Fee Schedule</a>.</li>
<li>Elastic N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) shares rose 16.29%. Wedbush Securities analyst Daniel Ives has significantly increased his optimism on the next phase of the AI revolution, focusing on its <a href="https://www.benzinga.com//node/42171519" target="_blank" rel="noreferrer noopener">transformative impact on the software sector</a>.</li>
<li>Ulta Beauty, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) shares upped 14.13%. Citigroup analysts raised the<a href="https://www.benzinga.com/quote/ulta/analyst-ratings" target="_blank" rel="noreferrer noopener"> price forecast on the stock</a>.</li>
<li>Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) <a href="https://www.benzinga.com//node/42197195" target="_blank" rel="noreferrer noopener">shares surged 12.58%</a> last week.</li>
<li>Ralph Lauren Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RL#NYSE">RL</a>) stock gained 11.72% last week.</li>
<li>Copart, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRT#NASDAQ">CPRT</a>) stock was up 11.41% after the company reported better-than-expected Q1 sales results.</li>
<li>Snap Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) stock increased 12.18%. Citigroup analysts raised the <a href="https://www.benzinga.com/quote/snap/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast on the stock</a>.</li>
</ol>
Photo by rblfmr via Shutterstock

Rivian Automotive, Rocket Lab And Moderna Are Among Top 10 Large-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio?

Bernstein analyst William Pickering maintains Arrowhead Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) with a Market Perform and lowers the price target from $27 to $24.

Bernstein Maintains Market Perform on Arrowhead Pharma, Lowers Price Target to $24

U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Wednesday.
Shares of Iris Energy Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>) rose sharply during Wednesday's session on the heels of the company's first-quarter financial results. Multiple analysts raised price <a href="https://www.benzinga.com/quote/IREN/earnings">targets following the print</a>.
After the market close on Tuesday, Iris reported first-quarter Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) mining revenue of $49.6 million. The company reported a 28% increase in AI Cloud Services revenue quarter-over-quarter to $3.2 million.
Iris Energy shares jumped 30.8% to $12.51 on Wednesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Agora, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/API#NASDAQ">API</a>) gained 26.1% to $5.98.</li>
<li>Arrowhead Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) shares gained 20.9% to $25.45 following FY 2024 results.</li>
<li>Murano Global Investments Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNO#NASDAQ">MRNO</a>) jumped 18.4% to $11.13.</li>
<li>Kingsoft Cloud Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>) gained 17.1% to $6.99.</li>
<li>Urban Outfitters, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>) shares surged 16% to $46.58 following third-quarter earnings. Citigroup upgraded the stock to Buy following the report.</li>
<li>Bit Digital, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTBT#NASDAQ">BTBT</a>) gained 14.4% to $4.2802.</li>
<li>Fate Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FATE#NASDAQ">FATE</a>) gained 14.4% to $3.0650.</li>
<li>Hut 8 Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) shares jumped 12.8% to $27.56.</li>
<li>Archer Aviation Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) gained 12.2% to $8.10.</li>
<li>MINISO Group Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNSO#NASDAQ">MNSO</a>) climbed 7.2% to $18.66.</li>
<li>Bloom Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) shares gained 5.8% to $27.69.</li>
<li>Ambarella, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMBA#NASDAQ">AMBA</a>) gained 5% to $71.82 after the company on Tuesday reported a year-over-year increase in third-quarter revenue results..</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42213467/urban-outfitters-to-rally-around-47-here-are-10-top-analyst-forecasts-for-wednesday">Urban Outfitters To Rally Around 47%? Here Are 10 Top Analyst Forecasts For Wednesday</a></li>
</ul>

$BTC

AMBA

BTBT

FATE

MNSO

MRNO

Iris Energy, Arrowhead Pharmaceuticals, Urban Outfitters And Other Big Stocks Moving Higher On Wednesday

Piper Sandler analyst Edward Tenthoff maintains Arrowhead Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) with a Overweight and lowers the price target from $62 to $45.

Piper Sandler Maintains Overweight on Arrowhead Pharma, Lowers Price Target to $45

Citigroup analyst Shawn Egan maintains Arrowhead Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) with a Neutral and lowers the price target from $27 to $26.

Citigroup Maintains Neutral on Arrowhead Pharma, Lowers Price Target to $26

WIIM

Arrowhead Pharmaceuticals shares are trading higher. Chardan Capital maintained a Buy rating on the stock.

<h3>Gainers</h3>
<ul>
<li>Poseida Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>) shares moved upwards by 224.5% to $9.28 during Tuesday's pre-market session. The company's market cap stands at $904.4 million. </li>
<li>Caribou Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBU#NASDAQ">CRBU</a>) stock rose 23.76% to $2.5. The company's market cap stands at $226.3 million. </li>
<li>Arrowhead Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) shares increased by 21.07% to $22.75. The market value of their outstanding shares is at $2.8 billion. As per the press release, Q4 earnings came out today. </li>
<li>Neurogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGNE#NASDAQ">NGNE</a>) stock rose 19.47% to $26.66. The market value of their outstanding shares is at $396.0 million. </li>
<li>Tactile Systems Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCMD#NASDAQ">TCMD</a>) stock increased by 18.12% to $22.35. The market value of their outstanding shares is at $536.3 million. </li>
<li>Embecta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EMBC#NASDAQ">EMBC</a>) stock increased by 18.04% to $17.01. The market value of their outstanding shares is at $981.5 million. As per the press release, Q4 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Select Medical Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEM#NYSE">SEM</a>) shares declined by 43.8% to $21.75 during Tuesday's pre-market session. The company's market cap stands at $2.8 billion. </li>
<li>Alector (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALEC#NASDAQ">ALEC</a>) stock declined by 34.35% to $2.6. The company's market cap stands at $254.6 million. </li>
<li>BrightSpring Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTSGU#NASDAQ">BTSGU</a>) shares fell 20.77% to $55.01. </li>
<li>Scinai Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNI#NASDAQ">SCNI</a>) shares decreased by 17.85% to $2.9. The market value of their outstanding shares is at $2.4 million. As per the news, the Q3 earnings report came out 2 days ago. </li>
<li>Cocrystal Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCP#NASDAQ">COCP</a>) stock declined by 10.14% to $1.95. The company's market cap stands at $19.8 million. </li>
<li>Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) shares fell 9.94% to $264.78. The market value of their outstanding shares is at $142.3 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALEC

BTSGU

COCP

CRBU

EMBC

NGNE

PSTX

SCNI

TCMD

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Arrowhead Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) reported quarterly losses of $(5.00) per share which missed the analyst consensus estimate of $(4.45) by 12.36 percent. The company reported quarterly sales of $3.551 million which missed the analyst consensus estimate of $74.932 million by 95.26 percent.

Earnings Misses

Arrowhead Pharma FY 2024 GAAP EPS $(5.00) Misses $(4.45) Estimate, Sales $3.551M Miss $74.932M Estimate

Arrowhead Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) shares are trading higher Tuesday after the company announced a global licensing and collaboration agreement with Sarepta Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>). Here&#8217;s <a href="https://www.benzinga.com/quote/ARWR/news">what you need to know.</a>
What To Know: The partnership grants Sarepta exclusive worldwide rights to Arrowhead's investigational RNA interference (RNAi) therapies for rare genetic diseases targeting muscle, the central nervous system (CNS) and the lungs.
The agreement focuses on Arrowhead's Targeted RNAi Molecule platform, which enables precise delivery of therapies designed to reduce the activity of disease-causing genes. 
Arrowhead will receive an upfront payment of $500 million, as well as a $325 million equity investment from Sarepta at a 35% premium. Additional terms include $250 million to be paid in $50 million installments over five years, up to $300 million in near-term milestone payments over the next year and potential tiered royalties on commercial sales.
Arrowhead CEO Christopher Anzalone called the agreement transformative, noting that the influx of capital extends the company's financial runway through 2028. This timeline positions Arrowhead to pursue the commercial launch of its first product, plozasiran, pending regulatory approval.
Sarepta sees the collaboration as a strategic expansion of its portfolio, complementing its expertise in gene therapy and Duchenne muscular dystrophy. Sarepta CEO Doug Ingram highlighted the potential for these RNAi programs to have a significant market impact. As part of the agreement, Ingram will join Arrowhead's Board of Directors.
Check This Out: <a href="https://www.benzinga.com/24/11/42195803/why-is-exact-sciences-stock-trading-higher-on-monday">Why Is Exact Sciences Stock Trading Higher On Monday?</a>
&#8220;The agreement affords multiple potential blockbuster opportunities, serves our strategic priorities for the remainder of the decade and beyond and diversifies our business model across one-time therapies and chronic treatments allowing for long-term growth and success,&#8221; Ingram said.
The collaboration is expected to close in early 2025, pending regulatory approval. Both companies have emphasized the agreement's significance in advancing treatments for rare genetic diseases, with additional details anticipated in their upcoming investor presentations.
ARWR Price Action: Arrowhead Pharmaceuticals shares were up 16.7% at $21.94 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1727794380964569"><img loading="lazy" decoding="async" width="1024" height="540" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26112407/ARWR-1024x540.png" alt="" class="wp-image-665810" style="width:497px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26112407/ARWR-1024x540.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26112407/ARWR-300x158.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26112407/ARWR-768x405.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26112407/ARWR.png 1140w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42194455/berry-global-sells-specialty-tapes-unit-for-540m-to-focus-on-consumer-growth">Merger-Bound Berry Global Agrees To Divest Specialty Tapes Unit For ~$540M</a></li>
</ul>
Image Via Shutterstock.

Arrowhead Pharmaceuticals Shares Are On The Rise Today: What's Going On?

U.S. stocks were mixed, with the Dow Jones index falling more than 200 points on Tuesday.
Shares of The J. M. Smucker Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SJM#NYSE">SJM</a>) rose sharply during Tuesday's session after the company reported better-than-expected second-quarter financial results and raised its FY25 adjusted EPS guidance with its <a href="https://www.benzinga.com/news/earnings/24/11/42189572/j-m-smucker-q2-earnings-beat-17-sales-surge-fy25-eps-outlook-boost-more">midpoint above estimates.</a>
Smucker shares surged 6.2% to $120.60 on Tuesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Hesai Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSAI#NASDAQ">HSAI</a>) shares jumped 59% to $7.55 after the company reported better-than-expected third-quarter sales results.</li>
<li>Embecta Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EMBC#NASDAQ">EMBC</a>) gained 30.2% to $18.76 after the company reported better-than-expected fourth-quarter financial results and issued FY25 adjusted EPS guidance above estimates.</li>
<li>LexinFintech Holdings Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LX#NASDAQ">LX</a>) surged 22.8% to $4.1750 after the company announced its board approved an amendment for a dividend policy to increase the payout ratio. Also, the company reported third-quarter financial results.</li>
<li>Semtech Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) gained 20.3% to $64.32 as the company reported better-than-expected third-quarter financial results and issued fourth-quarter guidance with its midpoint above estimates.</li>
<li>Arrowhead Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) gained 18.1% to $22.17 after the company entered into a global licensing and collaboration agreement with Sarepta Therapeutics for multiple clinical and preclinical siRNA programs.</li>
<li>Neurogene Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGNE#NASDAQ">NGNE</a>) shares rose 15% to $25.65.</li>
<li>SmartRent, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMRT#NYSE">SMRT</a>) gained 13.8% to $1.8450.</li>
<li>Sangamo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) gained 12.6% to $2.1850.</li>
<li>POET Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POET#NASDAQ">POET</a>) surged 12.2% to $4.77. POET Technologies recently announced plans to expand its capacity.</li>
<li>Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) shares gained 9.1% to $125.10 after the company announced a global licensing and collaboration agreement with Arrowhead Pharmaceuticals for multiple clinical and preclinical siRNA programs.</li>
<li>NRG Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>) gained 8% to $99.21 after Jefferies upgraded the stock from Hold to Buy and raised its price target from $93 to $113.</li>
<li>Exact Sciences Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) surged 7.8% to $59.45. The company announced it will present 10 abstracts at SABCS.</li>
<li>Woodward, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WWD#NASDAQ">WWD</a>) surged 7.4% to $192.62 after the company reported better-than-expected fourth-quarter EPS and sales.</li>
<li>Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) gained 7.3% to $25.82.</li>
<li>Hanesbrands Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HBI#NYSE">HBI</a>) gained 5.8% to $8.94. UBS analyst Jay Sole upgraded Hanesbrands from Neutral to Buy and raised the price target from $9 to $11.</li>
</ul>
Now Read This:
<ul>
<li> <a href="https://www.benzinga.com/24/11/42190113/starbucks-to-rally-around-13-here-are-10-top-analyst-forecasts-for-tuesday">Starbucks To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Tuesday</a></li>
</ul>

Intraday Update

HSAI

POET

SGMO

SMRT

SMTC

J.M. Smucker Posts Upbeat Earnings, Joins LexinFintech, Semtech, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday

Arrowhead Pharmaceuticals shares are trading higher after the company entered into a global licensing and collaboration agreement with Sarepta Therapeutics for multiple clinical and preclinical siRNA programs.

<h3>Companies Reporting Before The Bell</h3>
• Icecure Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCM#NASDAQ">ICCM</a>) is projected to report quarterly loss at $0.08 per share on revenue of $708 thousand. 
• Tsakos Energy Navigation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEN#NYSE">TEN</a>) is projected to report quarterly earnings at $0.66 per share on revenue of $164.00 million. 
• Manchester United (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MANU#NYSE">MANU</a>) is expected to report quarterly loss at $0.29 per share on revenue of $194.49 million. 
• Best Buy Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) is projected to report quarterly earnings at $1.29 per share on revenue of $9.63 billion. 
• Kohl's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) is likely to report quarterly earnings at $0.27 per share on revenue of $3.71 billion. 
• JM Smucker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SJM#NYSE">SJM</a>) is estimated to report quarterly earnings at $2.51 per share on revenue of $2.26 billion. 
• Dick's Sporting Goods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>) is expected to report quarterly earnings at $2.69 per share on revenue of $3.03 billion. 
• Analog Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NASDAQ">ADI</a>) is projected to report quarterly earnings at $1.64 per share on revenue of $2.41 billion. 
• Titan Machinery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TITN#NASDAQ">TITN</a>) is projected to report quarterly earnings at $0.05 per share on revenue of $675.30 million. 
• Embecta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EMBC#NASDAQ">EMBC</a>) is projected to report quarterly earnings at $0.36 per share on revenue of $276.88 million. 
• Ucloudlink Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCL#NASDAQ">UCL</a>) is expected to report quarterly earnings at $0.07 per share on revenue of $26.70 million. 
• Zhihu (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZH#NYSE">ZH</a>) is estimated to report earnings for its third quarter. 
• Macy's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/M#NYSE">M</a>) is expected to report quarterly loss at $0.01 per share on revenue of $4.72 billion. 
• Burlington Stores (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURL#NYSE">BURL</a>) is estimated to report quarterly earnings at $1.55 per share on revenue of $2.56 billion. 
• H World Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTHT#NASDAQ">HTHT</a>) is estimated to report quarterly earnings at $0.69 per share on revenue of $933.86 million. 
• Cadeler (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CDLR#NYSE">CDLR</a>) is likely to report earnings for its third quarter. 
• Abercrombie &amp; Fitch (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>) is projected to report quarterly earnings at $2.22 per share on revenue of $1.18 billion. 
• American Woodmark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMWD#NASDAQ">AMWD</a>) is projected to report quarterly earnings at $2.37 per share on revenue of $458.29 million. 
• Cheche Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCG#NASDAQ">CCG</a>) is projected to report earnings for its third quarter. 
• MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) is projected to report quarterly loss at $0.44 per share on revenue of $6.01 million. 
<h3>Companies Reporting After The Bell</h3>
• JOYY (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YY#NASDAQ">YY</a>) is expected to report quarterly earnings at $0.92 per share on revenue of $562.00 million. 
• Iris Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>) is estimated to report quarterly loss at $0.07 per share on revenue of $54.75 million. 
• 3D Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDD#NYSE">DDD</a>) is expected to report quarterly loss at $0.09 per share on revenue of $113.65 million. 
• Guess (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>) is expected to report quarterly earnings at $0.37 per share on revenue of $747.44 million. 
• Pinstripes Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNST#NYSE">PNST</a>) is projected to report quarterly loss at $0.21 per share on revenue of $30.59 million. 
• Urban Outfitters (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>) is likely to report quarterly earnings at $0.85 per share on revenue of $1.34 billion. 
• Nordstrom (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JWN#NYSE">JWN</a>) is estimated to report quarterly earnings at $0.22 per share on revenue of $3.35 billion. 
• CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) is estimated to report quarterly earnings at $0.81 per share on revenue of $983.03 million. 
• Dell Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) is estimated to report quarterly earnings at $2.06 per share on revenue of $24.72 billion. 
• Nutanix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTNX#NASDAQ">NTNX</a>) is likely to report quarterly earnings at $0.32 per share on revenue of $572.16 million. 
• Arrowhead Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) is expected to report quarterly loss at $0.92 per share on revenue of $58.91 million. 
• Autodesk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) is likely to report quarterly earnings at $2.12 per share on revenue of $1.56 billion. 
• Workday (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) is projected to report quarterly earnings at $1.76 per share on revenue of $2.13 billion. 
• Ambarella (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMBA#NASDAQ">AMBA</a>) is expected to report quarterly earnings at $0.04 per share on revenue of $79.03 million. 
• Yxt.Com Group Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YXT#NASDAQ">YXT</a>) is likely to report earnings for its third quarter. 
• Noah Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOAH#NYSE">NOAH</a>) is estimated to report earnings for its third quarter. 
• PagerDuty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PD#NYSE">PD</a>) is projected to report quarterly earnings at $0.17 per share on revenue of $116.39 million. 
• HP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>) is expected to report quarterly earnings at $0.93 per share on revenue of $14.00 billion. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADSK

AMWD

BURL

CDLR

CRWD

DELL

HTHT

ICCM

MANU

MDWD

NOAH

NTNX

PNST

TITN

WDAY

Earnings Scheduled For November 26, 2024

Arrowhead Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) is set to give its latest quarterly earnings report on Tuesday, 2024-11-26. Here's what investors need to know before the announcement.
Analysts estimate that Arrowhead Pharma will report an earnings per share (EPS) of $-1.05. 
The market awaits Arrowhead Pharma's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Performance in Previous Earnings</h3>
The company's EPS missed by $0.83 in the last quarter, leading to a 9.44% drop in the share price on the following day.
Here's a look at Arrowhead Pharma's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.55</td>
<td>-0.16</td>
<td>-0.82</td>
<td>-0.60</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.38</td>
<td>-1.02</td>
<td>-1.24</td>
<td>-1.02</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-9.0%</td>
<td>-11.0%</td>
<td>-5.0%</td>
<td>-27.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1732543293_0.png" alt="eps graph" />
<h3>Arrowhead Pharma Share Price Analysis</h3>
Shares of Arrowhead Pharma were trading at $18.54 as of November 22. Over the last 52-week period, shares are down 35.89%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/ARWR/earnings">To track all earnings releases for Arrowhead Pharma visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Look Ahead: Arrowhead Pharma's Earnings Forecast

Chardan Capital analyst Keay Nakae reiterated a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research Report) yesterday and set a price target o...

Promising Clinical Trial Results Boost Confidence in Arrowhead Pharmaceuticals, Justifying Buy Rating

In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research Report), wi...

Arrowhead Pharmaceuticals: Positioned for Growth with Strategic Partnerships and siRNA Advancements

Arrowhead Pharmaceuticals ( ($ARWR) ) just unveiled an announcement. Douglass Given, M.D., Ph.D., is retiring from Arrowhead Pharmaceuticals' Board...

Leadership Transition at Arrowhead Pharmaceuticals' Board

H.C. Wainwright analyst Patrick Trucchio believes the FDA approval of Ionis Pharmaceuticals' (IONS) Tryngolza, an oligonucleotide, for the treatmen...

Ionis FDA approval a positive for Arrowhead, says H.C. Wainwright

Arrowhead (ARWR) Pharmaceuticals announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-INHBE, the company's investig...

Arrowhead  doses 1st patients in study of ARO-INHBE for obesity treatment

2024's 'Biggest loses' that could see reversal in 2025

2024's 'Biggest losers' that could see reversal in 2025

B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research Report) yesterday and set a price ta...

Arrowhead Pharmaceuticals: Strong Growth Potential Backed by siRNA Therapeutics and Financial Stability

In a report released on January 7, Luca Issi from RBC Capital maintained a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research Report), with a...

Arrowhead Pharmaceuticals (ARWR) Receives a Buy from RBC Capital

Post the presentation at the 2025 JPMorgan Healthcare Conference by Sarepta (SRPT), JPMorgan notes the Elevidys launch remains strong with a solid ...

Sarepta's Elevidys launch remains strong with solid beat, says JPMorgan

ALGM

AMRK

ANSS

AZTA

CBRL

COHU

CTKB

DIOD

FIVE

GNTX

IONS

LSCC

POWI

QDEL

SDGR

SWKS

SYNA

VRSN

Press Releases

Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran

Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals Announces Global License and Collaboration Agreement with Sarepta Therapeutics for Multiple Clinical and Preclinical Programs

Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs

Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results

Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity

Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity

Comments

Arrowhead Pharma

뉴스

에 대한 최신 뉴스 Arrowhead Pharma (NASDAQ:ARWR) 주식

일요일, 12월 01, 2024

금요일, 5월 03, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌